Claims for Patent: 7,868,154

Summary for Patent: 7,868,154

Title:	Promoter to IL-18BP, its preparation and use
Abstract:	The present invention relates to the promoter of interleukin-18 binding protein (IL-18BP), to its preparation and use.
Inventor(s):	Rubinstein; Menachem (Rehovot, IL), Novick; Daniela (Rehovot, IL), Hurgin; Vladimir (Ashdod, IL)
Assignee:	Yeda Research and Development Co. Ltd. (IL)
Application Number:	10/530,963
Patent Claims:	1. An isolated DNA sequence comprising a functional human IL-18BP promoter sequence comprising the nucleotide sequence of SEQ ID NO: 1 and further comprising SEQ ID NO: 5 operably linked to the 3' end of SEQ ID NO:1. 2. The isolated DNA sequence according to claim 1, operably linked to an intron. 3. The isolated DNA sequence according to claim 2, wherein the intron consists of the first intron of IL-18BP. 4. The isolated DNA sequence according to claim 1, further comprising a gene operatively linked to the isolated DNA sequence. 5. The isolated DNA sequence according to claim 4, wherein the gene encodes IL-18BP. 6. The isolated DNA sequence according to claim 4, wherein the gene encodes a heterologous protein. 7. The isolated DNA sequence according to claim 6, wherein the heterologous protein is a luciferase protein. 8. The isolated DNA sequence according to claim 6, wherein the heterologous gene encodes a protein selected from an interferon-beta, a TNF, an erythropoietin, a tissue plasminogen activator, a granulocyte colony stimulating factor, a manganese-superoxide 41 dismutase, an immunoglobulin, an immunoglobulin fragment, a growth hormone, an FSH, an hCG, an IL-18, an hsLDLR and a TNF receptor binding protein. 9. A vector comprising the DNA sequence according to claim 1. 10. An isolated host cell comprising the vector according to claim 9. 11. The isolated host cell according to claim 10, which is a mammalian cell. 12. The isolated host cell according to claim 11, selected from the group consisting of CHO, WISH, HepG2, Cos, CV- 1.HeLA, and Hakat U937 cells. 13. A recombinant virus vector which comprises a portion of the virus genomic nucleic acid, a DNA fragment comprising a gene of interest and a DNA fragment comprising the DNA sequence according to claim 1, operably linked to the gene of interest. 14. The recombinant virus vector according to claim 13, wherein the gene of interest encodes a protein selected from an interferon-beta, a TNF, an erythropoietin, a tissue plasminogen activator, a granulocyte colony stimulating factor, a manganese-superoxide dismutase, an immunoglobulin, an immunoglobulin fragment, a growth hormone, an FSH, an hCG, an IL-18, an hsLDLR and a TNF receptor binding protein. 15. The recombinant virus vector according to claim 13, wherein the virus is an adeno-associated virus. 16. A pharmaceutical composition comprising the isolated DNA sequence of claim 1. 17. An isolated DNA sequence comprising a functional human IL-18BP promoter comprising the nucleotide sequence of SEQ ID NO: 1 and further comprising SEQ ID NO: 5 operably linked to the 3' end of SEQ ID NO:1 and wherein the promoter is mutated at one or more AP1 sites present in the silencer element present in SEQ ID NO: 1. 18. The isolated DNA sequence according to claim 17, further comprising an intron. 19. The isolated DNA sequence according to claim 18, wherein the intron consists of the first intron of IL-18BP. 20. The isolated DNA sequence according to claim 17, further comprising a gene operatively linked to the isolated DNA sequence. 21. The isolated DNA sequence according to claim 20, wherein the gene encodes IL-18BP. 22. The isolated DNA sequence according to claim 20, wherein the gene encodes a heterologous protein. 23. The isolated DNA sequence according to claim 22, wherein the heterologous protein is a luciferase protein. 24. The isolated DNA sequence according to claim 22, wherein the heterologous gene encodes a protein selected from an interferon-beta, a TNF, an erythropoietin, a tissue plasminogen activator, a granulocyte colony stimulating factor, a manganese-superoxide 41 dismutase, an immunoglobulin, or a fragment thereof, a growth hormone, an FSH, an hCG, an IL-18, an hsLDLR and a TNF receptor binding proteins. 25. A vector comprising the DNA sequence according to claim 17. 26. An isolated host cell comprising the vector according to claim 25. 27. The isolated host cell according to claim 26, which is a mammalian cell. 28. The isolated host cell according to claim 27, selected from the group consisting of CHO, WISH, HepG2, Cos, CV- 1.HeLA, and Hakat U937 cells. 29. A recombinant virus vector which comprises a portion of the virus genomic nucleic acid, a DNA fragment comprising a gene of interest and a DNA fragment comprising the DNA sequence according to claim 17, operably linked to the gene of interest. 30. The recombinant virus vector according to claim 29, wherein the gene of interest encodes a protein selected from an interferon-beta, a TNF, an erythropoietin, a tissue plasminogen activator, a granulocyte colony stimulating factor, a manganese-superoxide dismutase, an immunoglobulin, an immunoglobulin fragment, a growth hormone, an FSH, an hCG, an IL-18, an hsLDLR and a TNF receptor binding protein. 31. The recombinant virus vector according to claim 29, wherein the virus is an adeno-associated virus. 32. A pharmaceutical composition comprising the isolated DNA sequence of claim 17.

Details for Patent 7,868,154

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2022-10-10
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2022-10-10
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2022-10-10